A consensus statement from a National Cancer Institute–sponsored clinical trials planning meeting, reported in the Journal of Clinical Oncology by Park et al, presents revisions to the International Neuroblastoma Response Criteria (INRC) for assessing treatment response in patients with neuroblastoma.
The revision process involved multidisciplinary investigators from 13 countries, who reviewed data from published trials performed through cooperative groups, consortia, and single institutions. Monthly international conference calls were held from 2011 to 2015, with consensus on revisions being reached through review by working group leadership and the National Cancer Institute Clinical Trials Planning Meeting leadership council. Key revisions are reproduced/summarized here.
Key Revisions
The authors concluded: “These revised criteria will provide a uniform assessment of disease response, improve the interpretability of clinical trial results, and facilitate collaborative trial designs.”
The work was supported by the National Cancer Institute Pediatric and Adolescent Solid Tumor Steering Committee, Alex’s Lemonade Stand Foundation, Ben Towne Foundation, EVAN Foundation, Cancer Research UK Institute of Cancer Research (ICR), and National Institute for Health Research Research Methods Programme/ICR Biomedical Research Centre.
Julie R. Park, MD, of Seattle Children’s Hospital, is the corresponding author of the Journal of Clinical Oncology article.
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.